Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
TFF Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing drug products based on its patented Thin Film Freezing (TFF) technology platform in the United States and Australia.
It intends to focus on the development of inhaled dry powder drugs for the treatment of pulmonary diseases and conditions.
The company's drug candidates are TFF Voriconazole Inhalation Powder, which is in Phase II clinical trials for the treatment and prophylaxis of invasive pulmonary aspergillosis; and TFF Tacrolimus Inhalation Powder, which is in Phase II clinical trials used to prevent lung transplant rejection.
It also develops other dry powder products, such as Augmenta human derived monoclonal antibodies for the treatment of COVID-19 disease; and other vaccines.
It has a license agreement with the University of Texas at Austin for the development of inhaled dry powder drugs.
TFF Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Fort Worth, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 14, 24 | -1.22 Decreased by -771.43% | -1.70 Increased by +28.24% |
| May 14, 24 | -2.40 Decreased by -1.16 K% | -2.26 Decreased by -6.19% |
| Mar 28, 24 | -2.01 Decreased by -1.91 K% | -2.12 Increased by +5.19% |
| Nov 14, 23 | -0.09 Increased by +68.97% | -0.11 Increased by +18.18% |
| Aug 15, 23 | -0.14 Increased by +58.82% | -0.19 Increased by +26.32% |
| May 11, 23 | -0.19 Increased by +42.42% | -0.23 Increased by +17.39% |
| Mar 7, 23 | -0.10 Increased by +75.00% | -0.24 Increased by +58.33% |
| Nov 14, 22 | -0.29 Increased by +14.71% | -0.33 Increased by +12.12% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Jun 30, 24 | 650.22 K Increased by +95.06% | -4.48 M Increased by +10.78% | Decreased by -688.88% Increased by +54.26% |
| Mar 31, 24 | 203.27 K Increased by +295.25% | -5.74 M Increased by +16.80% | Decreased by -2.82 K% Increased by +78.95% |
| Dec 31, 23 | 733.87 K Increased by +N/A% | -4.76 M Increased by +35.46% | Decreased by -648.94% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -4.41 M Increased by +39.34% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 333.35 K Increased by +1.09 K% | -5.02 M Increased by +42.60% | Decreased by -1.51 K% Increased by +95.18% |
| Mar 31, 23 | 51.43 K Decreased by -23.74% | -6.89 M Increased by +17.70% | Decreased by -13.40 K% Decreased by -7.91% |
| Dec 31, 22 | 0.00 Increased by +100.00% | -7.38 M Increased by +26.57% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 22 | 0.00 Decreased by -100.00% | -7.27 M Increased by +16.25% | Decreased by N/A% Decreased by N/A% |